
|Articles|February 25, 2022
Unique Solutions to Semi-Solid Dosage Form ANDA Project
Author(s)LGM Pharma
When the patent on a brand-name dental paste expired, our client saw an opportunity to offer sufferers of painful oral lesions a generic alternative. Their product would drive down costs for patients while positioning the client’s business for success in a competitive market. With the FDA’s Abbreviated New Drug Application (ANDA) regulatory pathway leading the way forward, all they needed was a partner with experience developing and manufacturing unique semi-solid products. That’s when they found LGM Pharma. Read our case study.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
US Government Shutdown: Treating Regulatory Lapses as Predictable Operational Risks
2
How a Government Shutdown Causes FDA Inspection Bottlenecks and Backlogs
3
Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine
4
US Withdrawal From WHO Creates New Pharma Logistics Vulnerabilities
5